San Marcos, CA, United States of America

Manu Kanwar

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 9.7

ph-index = 1

Forward Citations = 17(Granted Patents)


Company Filing History:


Years Active: 2021-2025

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Manu Kanwar

Introduction

Manu Kanwar is a notable inventor based in San Marcos, CA. He has made significant contributions to the field of biomedical research, particularly in the development of antibodies targeting HIV. With a total of 3 patents to his name, his work is paving the way for advancements in HIV treatment and prevention.

Latest Patents

Manu Kanwar's latest patents focus on antibodies that target HIV gp120. These antibodies are designed to bind to HIV gp120 and neutralize the virus. The patents also disclose methods for using these antibodies, either alone or in combination with other therapeutic agents, to treat or prevent HIV infection. This innovative approach has the potential to significantly impact the lives of those affected by HIV.

Career Highlights

Manu Kanwar is currently employed at Gilead Sciences, Inc., a leading biopharmaceutical company. His work at Gilead has allowed him to collaborate with other experts in the field and contribute to groundbreaking research in HIV treatment. His dedication to innovation and research has established him as a key figure in the biomedical community.

Collaborations

Some of Manu Kanwar's notable coworkers include Brian A Carr and Magdeleine S Hung. Their collaborative efforts have further enhanced the research and development of effective therapies for HIV.

Conclusion

In summary, Manu Kanwar's contributions to the field of biomedical research, particularly in the development of HIV-targeting antibodies, are noteworthy. His work at Gilead Sciences, Inc. and his collaborations with other experts highlight his commitment to advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…